Aurinia Pharmaceuticals Inc. (AUPH) is a Biotechnology company in the Healthcare sector, currently trading at $16.07. It has a SharesGrow Score of 78/100, indicating a strong investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of AUPH = $13.77 (-14.3% from the current price, the stock appears overvalued). Analyst consensus target is AUPH = $16 (-3.5% upside).
Valuation: AUPH trades at a trailing Price-to-Earnings (P/E) of 7.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.25.
Financials: revenue is $283M, +28.4%/yr average growth. Net income is $287M, growing at +1676.1%/yr. Net profit margin is 101.5% (strong). Gross margin is 88.5% (-7.3 pp trend).
Balance sheet: total debt is $75M against $581M equity (Debt-to-Equity (D/E) ratio 0.13, conservative). Current ratio is 5.25 (strong liquidity). Debt-to-assets is 10%. Total assets: $752M.
Analyst outlook: 11 / 14 analysts rate AUPH as buy (79%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 84/100 (Pass), Growth 100/100 (Pass), Past 50/100 (Partial), Health 100/100 (Pass), Moat 55/100 (Partial), Future 59/100 (Partial), Income 100/100 (Pass).
